AGRX - アジャイル・セラピュ―ティクス (Agile Therapeutics Inc.)

AGRXのニュース

   Is the Options Market Predicting a Spike in Agile Therapeutics (AGRX) Stock?  2020/05/07 12:36:00 Zacks Investment Research
Investors need to pay close attention to Agile Therapeutics (AGRX) stock based on the movements in the options market lately.
   Agile Therapeutics Reports First Quarter 2020 Financial Results  2020/05/05 20:01:00 GlobeNewswire
FDA Approved Twirla® Expected to Reach Wholesalers in the Fourth Quarter of 2020 $93.9 Million in Cash and Cash Equivalents as of March 31, 2020 …
   The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace  2020/05/03 12:45:37 Benzinga
Biotech stocks started last week on a strong note but the upward momentum slowed through the week. The week saw a slew of earnings from big pharma names, including Merck & Co., Inc. (NYSE: MRK ) and Pfizer Inc. (NYSE: PFE ). Merck disappointed by lowering its outlook, although sell-side stayed positive on the prospects. Presentations at the American Association of Cancer Research Virtual Conference created some volatility. Verastem Inc (NASDAQ: VSTM ) became a casualty of "not-so-impressive" clinical data on its Phase 1 asset VS-6766 that targets KRAS mutant advanced solid tumors. The stock shed about 57% to a low of $1.77 before recovering some lost ground. Here are the key catalysts for the unfolding week. Conferences SunTrust Robinson Humphrey 6th Annual Life Sciences Summit (Virtual Conference): May 5–6 Maxim Group M-Vest Infectious Disease Virtual Conference: May 5 Related Link: A Deep Dive On Coronavirus Vaccine Plays Moderna, Inovio Clinical Readouts Adverum Biotechnologies Inc (NASDAQ: ADVM ) is scheduled to present new data from the OPTIC Phase1 clinical trial of ADVM-022 intravitreal gene therapy in wet age-related macular degeneration.
   Is Agile Therapeutics (AGRX) Stock Outpacing Its Medical Peers This Year?  2020/02/21 16:30:10 Zacks Investment Research
Is (AGRX) Outperforming Other Medical Stocks This Year?
   Agile Therapeutics EPS misses by $0.02  2020/02/20 21:25:11 Seeking Alpha
Agile Therapeutics (NASDAQ:AGRX): Q4 GAAP EPS of -$0.10 misses by $0.02. Cash and equivalents of $34.5M. Shares -14.3%. Press Release
   Is Agile Therapeutics (AGRX) Stock Outpacing Its Medical Peers This Year?  2020/02/21 16:30:10 Zacks Investment Research
Is (AGRX) Outperforming Other Medical Stocks This Year?
   Agile Therapeutics EPS misses by $0.02  2020/02/20 21:25:11 Seeking Alpha
Agile Therapeutics (NASDAQ:AGRX): Q4 GAAP EPS of -$0.10 misses by $0.02. Cash and equivalents of $34.5M. Shares -14.3%. Press Release
   Agile Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results  2020/02/20 21:01:00 GlobeNewswire
Current Cash and Cash Equivalents Expected to Meet Projected Operating Requirements through End of 2020 Twirla®, Company’s Lead Product Candidate,…
   Why This Analyst Sees New Contraceptive FDA Approval Doubling Agile Therapeutics Stock  2020/02/18 15:35:29 24/7 Wall street
   The Week Ahead In Biotech: Agile, Baudax Bio, Merck and Esperion Await FDA Decisions  2020/02/16 20:03:32 Benzinga
Biotech stocks were quiet in the week ending Feb. 14 amid some data readouts at a couple of conferences and earnings news flow from smid-cap companies. The following are key biotech catalysts to look forward to for the unfolding week: Conferences 34th German Cancer Conference: Feb 19-22 in Berlin, Germany International Association For The Study of Lung Cancer, or IASLC, 2020 Targeted Therapies of Lung Cancer Meeting: Feb. 19-22 in Santa Monica, California Related Link: 13 Key NASH Drug Candidates To Watch For In A Potential $30-Billion Market PDUFA Dates The FDA will rule on Agile Therapeutics Inc's (NASDAQ: AGR ) hormonal contraceptive patch Twirla by the PDUFA action date of Sunday. After two rejections in the past, Twirla managed to snag a positive Adcom verdict in October 2019. Late Monday, the company said it has negotiated a $35-million loan facility that has increased expectations concerning a positive verdict. The FDA is scheduled to issue its verdict on Merck & Co., Inc.'s (NYSE: MRK ) sBLAs for Keytruda dosing schedule updates.
   Is Agile Therapeutics (AGRX) Stock Outpacing Its Medical Peers This Year?  2020/02/21 16:30:10 Zacks Investment Research
Is (AGRX) Outperforming Other Medical Stocks This Year?
   Agile Therapeutics EPS misses by $0.02  2020/02/20 21:25:11 Seeking Alpha
Agile Therapeutics (NASDAQ:AGRX): Q4 GAAP EPS of -$0.10 misses by $0.02. Cash and equivalents of $34.5M. Shares -14.3%. Press Release
   Agile Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results  2020/02/20 21:01:00 GlobeNewswire
Current Cash and Cash Equivalents Expected to Meet Projected Operating Requirements through End of 2020 Twirla®, Company’s Lead Product Candidate,…
   Why This Analyst Sees New Contraceptive FDA Approval Doubling Agile Therapeutics Stock  2020/02/18 15:35:29 24/7 Wall street
   The Week Ahead In Biotech: Agile, Baudax Bio, Merck and Esperion Await FDA Decisions  2020/02/16 20:03:32 Benzinga
Biotech stocks were quiet in the week ending Feb. 14 amid some data readouts at a couple of conferences and earnings news flow from smid-cap companies. The following are key biotech catalysts to look forward to for the unfolding week: Conferences 34th German Cancer Conference: Feb 19-22 in Berlin, Germany International Association For The Study of Lung Cancer, or IASLC, 2020 Targeted Therapies of Lung Cancer Meeting: Feb. 19-22 in Santa Monica, California Related Link: 13 Key NASH Drug Candidates To Watch For In A Potential $30-Billion Market PDUFA Dates The FDA will rule on Agile Therapeutics Inc's (NASDAQ: AGR ) hormonal contraceptive patch Twirla by the PDUFA action date of Sunday. After two rejections in the past, Twirla managed to snag a positive Adcom verdict in October 2019. Late Monday, the company said it has negotiated a $35-million loan facility that has increased expectations concerning a positive verdict. The FDA is scheduled to issue its verdict on Merck & Co., Inc.'s (NYSE: MRK ) sBLAs for Keytruda dosing schedule updates.

calendar